Corvus Pharmaceuticals Inc. (C17)
XDUS
Real-time Data
06:00 AM
Day's Range
9.1552 wk Range
5.44Profile - C17 - Corvus Pharmaceuticals Inc.
Profile
Mic Code
XDUS
Sector
Healthcare
Industry
Biotechnology
Employees
37
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer. Corvus Pharmaceuticals Inc. centers its current work on immune modulator product candidates that target pathways involved in immune cell activation, signaling, and function. Its pipeline includes soquelitinib, a lead ITK inhibitor, along with other programs such as anti-CD73, A2AR, A2BR, and anti-CXCR2 approaches. The company’s research spans solid tumors, T-cell lymphomas, autoimmune disorders, allergic conditions, and infectious diseases. Corvus Pharmaceuticals Inc. is positioned in the biotechnology sector as a development-stage company advancing novel drug candidates through clinical evaluation, with a business model built around drug discovery, clinical development, and scientific partnerships.
Profile Details
Type
Common Stock
Address
901 Gateway Boulevard
City
South San Francisco
State
CA
Zip
94080
Country
United States
Phone
650 900 4520
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
